tknife_logo_new.png
T-knife Completes €66 Million Series A Financing to Develop Next-Generation T-Cell Therapies
August 06, 2020 05:30 ET | T-knife GmbH
T-knife’s proprietary humanized mouse platform (HuTCR) T-cell receptors expected to provide superior affinity/specificity properties Series A round led by Versant Ventures and RA Capital Management,...